, NIH Consensus Development Panel on Osteoporosis, JAMA, vol.285, pp.785-95, 2001.

M. Tinetti, M. Speechley, and S. Ginter, Risk Factors for Falls among Elderly Persons Living in the Community, New England Journal of Medicine, vol.319, issue.26, pp.1701-1708, 1988.
DOI : 10.1056/NEJM198812293192604

A. Milat, W. Watson, C. Monger, M. Barr, M. Giffin et al., Prevalence, circumstances and consequences of falls among community-dwelling older people: results of the 2009 NSW Falls Prevention Baseline Survey, New South Wales Public Health Bulletin, vol.22, issue.4, pp.43-51, 2011.
DOI : 10.1071/NB10065

M. Maravic, L. Bihan, C. Landais, P. Fardellone, and P. , Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database, Osteoporosis International, vol.13, issue.12, pp.1475-80, 2005.
DOI : 10.1016/S0020-1383(99)00248-X

K. Briot, M. Maravic, and C. Roux, Changes in number and incidence of hip fractures over 12 years in France, Bone, vol.81, pp.131-138, 2015.
DOI : 10.1016/j.bone.2015.07.009

T. Thomas, P. Gabach, and D. Buchon, Évaluation de la prise en charge avant et après hospitalisation pour fracture de fragilité en France à partir des dossiers de la SNIIRAM, 2015.

D. Solomon, S. Johnston, N. Boytsov, D. Mcmorrow, J. Lane et al., Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011, Journal of Bone and Mineral Research, vol.17, issue.1, pp.1929-1966, 2014.
DOI : 10.1308/003588409X432400
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.2202

E. Leblanc, T. Hillier, and K. Pedula, Hip Fracture and Increased Short-term but Not Long-term Mortality in Healthy Older Women, Archives of Internal Medicine, vol.171, issue.20, pp.1831-1838, 2011.
DOI : 10.1001/archinternmed.2011.447

L. Melton, S. Achenbach, E. Atkinson, T. Therneau, and S. Amin, Long-term mortality following fractures at different skeletal sites: a population-based cohort study, Osteoporosis International, vol.20, issue.5, pp.1689-1698, 2013.
DOI : 10.1007/s00198-008-0742-8
URL : http://europepmc.org/articles/pmc3630278?pdf=render

D. Bliuc, N. Nguyen, and V. Milch, Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women, JAMA, vol.301, issue.5, pp.513-534, 2009.
DOI : 10.1001/jama.2009.50

J. Clinton, A. Franta, N. Polissar, B. Neradilek, D. Mounce et al., Proximal Humeral Fracture as a Risk Factor for Subsequent Hip Fractures, The Journal of Bone and Joint Surgery-American Volume, vol.91, issue.3, pp.503-514, 2009.
DOI : 10.2106/JBJS.G.01529

D. Bliuc, T. Nguyen, J. Eisman, and J. Center, The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.415-438, 2014.
DOI : 10.1210/jc.2013-3461

M. Cuddihy, S. Gabriel, C. Crowson, O. Fallon, W. Melton et al., Forearm Fractures as Predictors of Subsequent Osteoporotic Fractures, Osteoporosis International, vol.9, issue.6, pp.469-75, 1999.
DOI : 10.1007/s001980050172

R. Lindsay, S. Silverman, and C. Cooper, Risk of New Vertebral Fracture in the Year Following a Fracture, JAMA, vol.285, issue.3, pp.320-323, 2001.
DOI : 10.1001/jama.285.3.320

S. Fujiwara, F. Kasagi, N. Masunari, K. Naito, G. Suzuki et al., Fracture Prediction From Bone Mineral Density in Japanese Men and Women, Journal of Bone and Mineral Research, vol.44, issue.8, pp.1547-53, 2003.
DOI : 10.7326/0003-4819-114-11-919
URL : https://www.onlinelibrary.wiley.com/doi/pdf/10.1359/jbmr.2003.18.8.1547

E. Sornay-rendu, F. Munoz, P. Garnero, F. Duboeuf, and P. Delmas, Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study, Journal of Bone and Mineral Research, vol.18, issue.Suppl 6, pp.1813-1822, 2005.
DOI : 10.1007/s001980050172

O. Johnell, J. Kanis, and A. Oden, Predictive Value of BMD for Hip and Other Fractures, Journal of Bone and Mineral Research, vol.69, issue.Suppl 2, pp.1185-94, 2005.
DOI : 10.1093/oxfordjournals.aje.a008920

D. Bates and D. Black, Cummings SR Clinical use of bone densitometry : clinical applications

, JAMA, vol.288, pp.1898-900, 2002.

S. Cummings, D. Black, and M. Nevitt, Bone density at various sites for prediction of hip fractures, The Lancet, vol.341, issue.8837, pp.72-77, 1993.
DOI : 10.1016/0140-6736(93)92555-8

S. Sc, M. Van-der-klift, A. Weel, C. De-laet, H. Burger et al., Fracture incidence and association with bone mineral density in elderly men and women : the Rotterdam Study, Bone, vol.34, pp.195-202, 2004.

E. Siris, Y. Chen, and T. Abbott, Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures, Archives of Internal Medicine, vol.164, issue.10, pp.1108-1120, 2004.
DOI : 10.1001/archinte.164.10.1108
URL : http://archinte.jamanetwork.com/data/journals/intemed/5486/ioi30223.pdf

S. Wainwright, L. Marshall, and K. Ensrud, Hip Fracture in Women without Osteoporosis, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.5, pp.2787-93, 2005.
DOI : 10.1210/jc.2004-1568

A. Schwartz, E. Vittinghoff, and D. Bauer, Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes, JAMA, vol.305, issue.21, pp.2184-92, 2011.
DOI : 10.1001/jama.2011.715

M. Premaor, K. Ensrud, L. Lui, R. Parker, J. Cauley et al.,

, Study of Osteoporotic Fractures Risk factors for nonvertebral fracture in obese older women, J Clin Endocrinol Metab, vol.96, pp.2414-2435, 2011.

M. Premaor, L. Pilbrow, C. Tonkin, R. Parker, and J. Compston, Obesity and fractures in postmenopausal women, Journal of Bone and Mineral Research, vol.62, issue.2, pp.292-299, 2010.
DOI : 10.1259/bjr.72.859.10624323

M. Yamamoto, T. Yamaguchi, M. Yamauchi, H. Kaji, and T. Sugimoto, Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications, Journal of Bone and Mineral Research, vol.24, issue.4, pp.702-711, 2009.
DOI : 10.1359/jbmr.081207

M. Gnant, B. Mlineritsch, and G. Luschin-ebengreuth, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer : 5-year follow-up of the ABCSG-12

, bone-mineral density substudy, Lancet, vol.386, pp.433-476, 2015.

P. Dargent-molina, F. Favier, and H. Grandjean, Fall-related factors and risk of hip fracture: the EPIDOS prospective study, The Lancet, vol.348, issue.9021, pp.145-154, 1996.
DOI : 10.1016/S0140-6736(96)01440-7

, British geriatrics Society clinical practice guideline : prevention of falls in older persons, pp.34-48, 2010.

H. Blain, T. Masud, and P. Dargent-molina, A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement, The journal of nutrition, health & aging, vol.165, issue.8610, pp.647-52, 2016.
DOI : 10.1001/archinte.165.8.905
URL : https://hal.archives-ouvertes.fr/hal-01867184

J. Kanis, O. Johnell, A. Oden, H. Johansson, and E. Mccloskey, FRAX??? and the assessment of fracture probability in men and women from the UK, Osteoporosis International, vol.17, issue.Suppl 2, pp.385-97, 2008.
DOI : 10.1093/qjmed/hci029

K. Briot, B. Cortet, and T. Thomas, 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, Joint Bone Spine, vol.79, issue.3, pp.304-317, 2012.
DOI : 10.1016/j.jbspin.2012.02.014

K. Briot, S. Paternotte, and S. Kolta, FRAX??: Prediction of Major Osteoporotic Fractures in Women from the General Population: The OPUS Study, PLoS ONE, vol.22, issue.12, p.83436, 2013.
DOI : 10.1371/journal.pone.0083436.t009

E. Sornay-rendu, F. Munoz, P. Delmas, and R. Chapurlat, The FRAX tool in French women: How well does it describe the real incidence of fracture in the OFELY cohort, Journal of Bone and Mineral Research, vol.21, issue.10, pp.2101-2108, 2010.
DOI : 10.1002/jbmr.106

F. Trémollieres, J. Pouillès, N. Drewniak, J. Laparra, C. Ribot et al., Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: Sensitivity of the WHO FRAX tool, Journal of Bone and Mineral Research, vol.355, issue.5, pp.1002-1011, 2010.
DOI : 10.1056/NEJMp068249

C. Couris, R. Chapurlat, J. Kanis, H. Johansson, P. Delmas et al., FRAX?? probabilities and risk of major osteoporotic fracture in France, Osteoporosis International, vol.18, issue.3, pp.2321-2328, 2012.
DOI : 10.1007/s00198-006-0245-4

V. Bousson, C. Bergot, and B. Sutter, Trabecular Bone Score: Where are we now?, Joint Bone Spine, vol.82, issue.5, pp.320-325, 2015.
DOI : 10.1016/j.jbspin.2015.02.005

W. Leslie, H. Johansson, J. Kanis, O. Lamy, A. Oden et al., Lumbar spine texture enhances 10-year fracture probability assessment, Osteoporosis International, vol.28, issue.9, pp.2271-2278, 2014.
DOI : 10.1002/jbmr.1775

W. Leslie, B. Aubry-rozier, L. Lix, S. Morin, and S. Majumdar, Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: The Manitoba Bone Density Program, Bone, vol.67, pp.10-14, 2014.
DOI : 10.1016/j.bone.2014.06.034

E. Mccloskey, A. Odén, and N. Harvey, Analysis of Trabecular Bone Score Osteoporos Int, vol.22, pp.391-420, 2015.

S. Vasikaran, R. Eastell, and O. Bruyère, Fracture Risk Prediction and Its Relationship to FRAX

, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment : a need for international reference standards, Osteoporos int, vol.22, pp.391-420

J. Cauley, J. Robbins, and Z. Chen, Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>, JAMA, vol.290, issue.13, pp.1729-1767, 2003.
DOI : 10.1001/jama.290.13.1729

B. Ettinger, D. Black, and B. Mitlakj, Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial, Obstetrical & Gynecological Survey, vol.55, issue.1
DOI : 10.1097/00006254-200001000-00021

, JAMA, vol.282, pp.637-682, 1999.

D. Black, S. Cummings, and D. Karpf, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, The Lancet, vol.348, issue.9041, pp.1535-1576, 1996.
DOI : 10.1016/S0140-6736(96)07088-2

, Page, vol.35, p.48

S. Cummings, D. Black, and D. Thompson, Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>, JAMA, vol.280, issue.24
DOI : 10.1001/jama.280.24.2077

, JAMA, vol.280, pp.2077-82, 1998.

A. Cranney, G. Wells, and A. Willan, II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women, Endocrine Reviews, vol.23, issue.4, pp.508-524, 2002.
DOI : 10.1210/er.2001-2002

G. Wells, A. Cranney, and J. Peterson, Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database of Systematic Reviews, vol.144, issue.10, p.1155, 2008.
DOI : 10.7326/0003-4819-144-10-200605160-00009

S. Harris, N. Watts, and H. Genant, Effect of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis

, JAMA, vol.282, pp.1344-52, 1999.

J. Reginster, H. Minne, and O. Sorensen, Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis, Osteoporosis International, vol.11, issue.1, pp.83-91, 2000.
DOI : 10.1007/s001980050010

G. Wells, A. Cranney, and J. Peterson, Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database of Systematic Reviews, vol.144, issue.10, p.4523, 2008.
DOI : 10.7326/0003-4819-144-10-200605160-00009

S. Boonen, M. Mcclung, R. Eastell, . El-hajj-fuleihan, I. Barton et al., Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old, Journal of the American Geriatrics Society, vol.4, issue.(S, pp.1832-1841, 2004.
DOI : 10.1007/978-3-642-70709-4_34

D. Black, P. Delmas, and R. Eastell, Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis, New England Journal of Medicine, vol.356, issue.18, pp.1809-1831, 2007.
DOI : 10.1056/NEJMoa067312

K. Lyles, C. Colón-emeric, and J. Magaziner, Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture, N Engl J Med, vol.357, p.40967, 2007.

S. Boonen, D. Black, and C. Colón-emeric, Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5???mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older, Journal of the American Geriatrics Society, vol.20, issue.2, pp.2-92, 2010.
DOI : 10.1007/s00198-004-1652-z

R. Neer, C. Arnaud, and J. Zanchetta, Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.344, issue.19, pp.1434-1475, 2001.
DOI : 10.1056/NEJM200105103441904

S. Cummings, S. Martin, J. Mcclung, and M. , Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.361, issue.8, pp.756-65, 2009.
DOI : 10.1056/NEJMoa0809493
URL : http://medicine.tums.ac.ir:803/Users/ramin_espandar/journal club 3%2C88/Denosumab for Prevention of Fractures in.PDF

D. Karpf, D. Shapiro, and E. Seeman, Prevention of Nonvertebral Fractures by Alendronate, JAMA, vol.277, issue.14, pp.1159-64, 1997.
DOI : 10.1001/jama.1997.03540380073035

M. Clung, P. Gensens, and P. Miller, Effect of risedronate on the risk of hip fracture in elderly women, N Engl J Med, vol.344, pp.333-340, 2001.

S. Papapoulos, Q. Sa, and U. Liberman, Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women, Osteoporosis International, vol.343, issue.5, pp.468-74, 2005.
DOI : 10.1007/s00198-004-1725-z

K. Ganda, M. Puech, and J. Chen, Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis, Osteoporosis International, vol.95, issue.7, pp.393-406, 2013.
DOI : 10.1002/jbmr.533

K. Huntjens, T. Van-geel, and J. Van-den-bergh, Fracture Liaison Service, The Journal of Bone & Joint Surgery, vol.96, issue.4, p.29, 2014.
DOI : 10.2106/JBJS.L.00223

H. Blain, Y. Rolland, and O. Beauchet, Usefulness of bone density measurement in fallers, Joint Bone Spine, vol.81, issue.5, pp.403-411, 2014.
DOI : 10.1016/j.jbspin.2014.01.020
URL : https://hal.archives-ouvertes.fr/hal-01128189

L. Gillespie, M. Robertson, and W. Gillespie, Interventions for preventing falls in older people living in the community, Cochrane Database Syst Rev, issue.9, p.7146, 2012.
DOI : 10.1002/14651858.cd007146.pub2
URL : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007146.pub2/pdf/abstract

F. El-khoury, B. Cassou, M. Charles, and P. Dargent-molina, The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults:, British Journal of Sports Medicine, vol.49, issue.20, p.6234, 2013.
DOI : 10.1136/bmj.f6234
URL : https://hal.archives-ouvertes.fr/tel-01170071

F. El-khoury, B. Cassou, A. Latouche, P. Aegerter, M. Charles et al., Effectiveness of two year balance training programme on prevention of fall induced injuries in at risk women aged 75-85 living in community: Oss??bo randomised controlled trial, BMJ, vol.351, p.3830, 2015.
DOI : 10.1136/bmj.h3830

T. Gill, M. Pahor, and J. Guralnik, Effect of structured physical activity on prevention of serious fall injuries in adults aged 70-89: randomized clinical trial (LIFE Study), BMJ, vol.352, p.245, 2016.
DOI : 10.1136/bmj.i245

M. Bolland, P. Barber, and R. Doughty, Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial, BMJ, vol.336, issue.7638, pp.262-268, 2008.
DOI : 10.1136/bmj.39440.525752.BE
URL : http://www.bmj.com/content/bmj/336/7638/262.full.pdf

M. Bolland, A. Avenell, J. Baron, A. Grey, G. Maclennan et al., Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis, BMJ, vol.341, issue.jul29 1, p.3691, 2010.
DOI : 10.1136/bmj.c3691

K. Pentti, M. Tuppurainen, and R. Honkanen, Use of calcium supplements and the risk of coronary heart disease in 52???62-year-old women: The Kuopio Osteoporosis Risk Factor and Prevention Study, Maturitas, vol.63, issue.1, pp.73-81, 2009.
DOI : 10.1016/j.maturitas.2009.03.006

M. Bolland, A. Grey, A. Avenell, G. Gamble, and I. Reid, Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis, BMJ, vol.342, issue.apr19 1, p.2040, 2011.
DOI : 10.1136/bmj.d2040

K. Sanders, A. Stuart, and E. Williamson, Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women, JAMA, vol.303, issue.18, pp.1815-1837, 2010.
DOI : 10.1001/jama.2010.594
URL : http://jama.jamanetwork.com/data/journals/jama/4511/joc05053_1815_1822.pdf

K. Richardson, K. Bennett, and R. Kenny, Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults, Age and Ageing, vol.24, issue.8, pp.90-96, 2015.
DOI : 10.2165/00002512-200724080-00006
URL : https://academic.oup.com/ageing/article-pdf/44/1/90/9134212/afu141.pdf

Z. Teng, Y. Zhu, F. Wu, Y. Zhu, X. Zhang et al., Opioids Contribute to Fracture Risk: A Meta-Analysis of 8 Cohort Studies, PLOS ONE, vol.17, issue.6, p.128232, 2015.
DOI : 10.1371/journal.pone.0128232.t003
URL : https://doi.org/10.1371/journal.pone.0128232

K. Siminoski, G. Jiang, J. Adachi, and . Hanley, Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures, Osteoporosis International, vol.61, issue.4, pp.403-410, 2005.
DOI : 10.1007/s00198-004-1709-z

K. Siminoski, R. Warshawski, J. H. Lee, and K. , The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women, Osteoporosis International, vol.115, issue.2, pp.290-296, 2006.
DOI : 10.4158/EP.9.6.544

K. Briot, E. Legrand, D. Pouchain, S. Monnier, and C. Roux, Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women, Canadian Medical Association Journal, vol.182, issue.6, pp.558-62, 2010.
DOI : 10.1503/cmaj.090710
URL : http://www.cmaj.ca/content/182/6/558.full.pdf

A. Modi, S. Sen, and J. Adachi, Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients : results from the Medication Use Patterns, p.93

, Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS), Osteoporos Int, vol.28, issue.10, pp.2867-76, 2017.

P. Ravaud, J. Reny, B. Giraudeau, R. Porcher, M. Dougados et al., Individual Smallest Detectable Difference in Bone Mineral Density Measurements, Journal of Bone and Mineral Research, vol.52, issue.8, pp.1449-56, 1999.
DOI : 10.7326/0003-4819-104-6-817

R. Jacques, S. Boonen, F. Cosman, I. Reid, D. Bauer et al., Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT), Journal of Bone and Mineral Research, vol.18, issue.6, pp.1627-1661, 2012.
DOI : 10.1359/jbmr.2003.18.6.1051

M. Austin, Y. Yang, and E. Vittinghoff, Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, Journal of Bone and Mineral Research, vol.25, issue.Suppl 1, pp.687-93, 2012.
DOI : 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1

D. Bauer, A. Schwartz, and L. Palermo, Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy, JAMA Internal Medicine, vol.174, issue.7, pp.1126-1160, 2014.
DOI : 10.1001/jamainternmed.2014.1232

F. Cosman, J. Cauley, and R. Eastell, Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.12, pp.4546-54, 2014.
DOI : 10.1210/jc.2014-1971

S. Ferrari, J. Adachi, and K. Lippuner, Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3??years, Osteoporosis International, vol.29, issue.12, pp.2763-71, 2015.
DOI : 10.1002/jbmr.2069

A. Khan, A. Morrison, and D. Hanley, Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus, Journal of Bone and Mineral Research, vol.37, issue.9, pp.3-23, 2015.
DOI : 10.1016/j.bjoms.2005.05.012

E. Shane, D. Burr, and B. Abrahamsen, Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research, Journal of Bone and Mineral Research, vol.52, issue.3, pp.1-23, 2014.
DOI : 10.1016/j.bone.2012.10.006

L. Gedmintas, D. Solomon, and S. Kim, Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis, Journal of Bone and Mineral Research, vol.366, issue.22, pp.1729-1766, 2013.
DOI : 10.1056/NEJMp1202623

C. Cardwell, C. Abnet, M. Cantwell, and L. Murray, Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer, JAMA, vol.304, issue.6, pp.657-63, 2010.
DOI : 10.1001/jama.2010.1098

. Group, Effects of continuing or stopping alendronate after 5 years of treatment : the Fracture Intervention Trial Long-term Extension (FLEX) : a randomized trial, JAMA, vol.296, pp.2927-2965, 2006.

D. Mellström, O. Sörensen, S. Goemaere, C. Roux, T. Johnson et al., Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis, Calcified Tissue International, vol.6, issue.S1, pp.462-470, 2004.
DOI : 10.1007/s001980070004

S. Martino, J. Cauley, and E. Barrett-connor, Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst, vol.196, pp.1751-61

D. Black, I. Reid, and J. Cauley, The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT), Journal of Bone and Mineral Research, vol.356, issue.5, pp.934-978, 2015.
DOI : 10.1056/NEJMc076132

H. Bone, R. Wagman, and M. Brandi, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, The Lancet Diabetes & Endocrinology, vol.5, issue.7, pp.2213-8587, 2017.
DOI : 10.1016/S2213-8587(17)30138-9

R. Lindsay, W. Scheele, and R. Neer, Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis, Archives of Internal Medicine, vol.164, issue.18, pp.2024-2054, 2004.
DOI : 10.1001/archinte.164.18.2024
URL : http://archinte.jamanetwork.com/data/journals/intemed/5501/ioi30700.pdf

R. Prince, A. Sipos, A. Hossain, and U. Syversen, Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment, Journal of Bone and Mineral Research, vol.15, issue.9, pp.1507-1520, 2005.
DOI : 10.1359/JBMR.050501
URL : http://onlinelibrary.wiley.com/doi/10.1359/JBMR.050501/pdf

B. Leder, J. Tsai, A. Uihlein, P. Wallace, H. Lee et al., Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial, The Lancet, vol.386, issue.9999, pp.1147-55, 2015.
DOI : 10.1016/S0140-6736(15)61120-5

N. Freemantle, S. Satram-hoang, and E. Tang, Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women, Osteoporosis International, vol.22, issue.1, pp.317-343, 2012.
DOI : 10.1007/s00198-010-1424-x

S. Cummings, S. Ferrari, and R. Eastell, Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension, Journal of Bone and Mineral Research, vol.27, issue.5, pp.190-198, 2018.
DOI : 10.1007/s00198-016-3553-3

D. Kendler, C. Roux, and C. Benhamou, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy, Journal of Bone and Mineral Research, vol.17, issue.1, pp.72-81, 2010.
DOI : 10.1016/S0002-9440(10)64556-7
URL : http://onlinelibrary.wiley.com/doi/10.1359/jbmr.090716/pdf

C. Roux, L. Hofbauer, and P. Ho, Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study, Bone, vol.58, pp.48-54, 2014.
DOI : 10.1016/j.bone.2013.10.006
URL : https://doi.org/10.1016/j.bone.2013.10.006

P. Miller, N. Pannacciulli, and J. Brown, Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.8
DOI : 10.1210/jc.2016-1801
URL : https://academic.oup.com/jcem/article-pdf/101/8/3163/10428648/jcem3163.pdf

R. Vert and N. , Harris) Vert MN (Reginster) Hip Study (McClung) Metaanalysis (Wells) Metaanalysis

, 90) NS Women with at least one vertebral fracture Women with at least two vertebral fractures Only in women with osteoporosis aged 70-79

, RFT (Lyles) Pooled analysis of individuals ?75 years (Boonen) 3 years 3 years 3 years 0, Post hoc analysis in individuals ?80 years Zoledronic acid HORIZON PFT

, In hip fracture patients: hip fracture 0.70 (0.41-1.19) Post-hoc analysis

P. Teriparatide and . Neer,

, Denosumab FREEDOM (Cummings) 3 years 0